RXi Pharmaceuticals Corp. (RXII) Trading Down 2.5%
RXi Pharmaceuticals Corp. (NASDAQ:RXII) shares were down 2.5% during trading on Thursday . The company traded as low as $2.23 and last traded at $2.31, with a volume of 52,835 shares trading hands. The stock had previously closed at $2.37.
A number of research analysts have recently commented on RXII shares. Zacks Investment Research raised shares of RXi Pharmaceuticals Corp. from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Friday, June 10th. HC Wainwright started coverage on shares of RXi Pharmaceuticals Corp. in a research report on Tuesday, June 7th. They issued a “buy” rating and a $3.50 price objective for the company.
The stock’s market capitalization is $15.09 million. The company’s 50-day moving average price is $2.43 and its 200 day moving average price is $2.52.
RXi Pharmaceuticals Corp. (NASDAQ:RXII) last posted its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.02. During the same quarter in the prior year, the business earned ($0.50) earnings per share. On average, analysts expect that RXi Pharmaceuticals Corp. will post ($1.50) earnings per share for the current year.
RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, primarily in the areas of dermatology and ophthalmology. The Company’s development programs are based on its siRNA technology and immunotherapy agents. Its clinical development programs include self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring, and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.